TROPiCS-02 Data Reinforce Role of Sacituzumab Govitecan as a SOC in HR+ Breast Cancer
August 29th 2023Sara M. Tolaney, MD, MPH, highlights updated survival and safety data seen with sacituzumab govitecan in patients with hormone receptor–positive, HER2-negative breast cancer; underscores how Trop-2 and HER2 testing is not necessarily needed for this agent in this population at this time; and shares how ongoing efforts are exploring the utilization of this agent earlier in the treatment course.
Read More
Trastuzumab Deruxtecan May Represent Potential Option for HER2-Expressing Solid Tumors
August 28th 2023Funda Meric-Bernstam, MD, discusses the design of the DESTINY-PanTumor02 trial, details the antitumor activity and safety of T-DXd in HER2-expressing solid tumors, and shares additional analyses that will be coming down the pike.
Read More
Petrylak Provides Perspective on the Nationwide Cisplatin/Carboplatin Shortage
August 28th 2023Daniel P. Petrylak, MD, discusses strategies he and his colleagues at Yale Cancer Center have employed to reduce the effect of the current chemotherapy shortage on patients, and emphasizes the need to reassess current manufacturing strategies in an effort to potentially mitigate future drug shortages.
Read More
CGX1321 Demonstrates Safety and Promising Activity in Advanced GI Cancers
August 21st 2023Marios Giannakis, MD, PhD, discusses how targeting the WNT signaling pathway could harness a previously underutilized pathway involved in GI tumor development, spotlights the activity and safety of CGX1321 with or without pembrolizumab in phase 1 studies, and emphasizes the need for continued investigation of CGX1321 to further validate this precision medicine approach.
Read More
Talquetamab Helps Usher in Era of Bispecific Antibodies in Relapsed/Refractory Myeloma
August 18th 2023Ajai Chari, MD, discusses how the FDA approval of talquetamab addresses several unmet needs in relapsed/refractory multiple myeloma and expands on the agent’s efficacy data and safety profile observed in MonumenTAL-1.
Read More
Randall Discusses the Importance of Identifying and Managing Chondroblastoma in Clinical Practice
August 16th 2023R. Lor Randall, MD, FACS, explains the difference between noncancerous chondroblastoma and other bone neoplasms, details the typical diagnosis and treatment of this rare condition, and emphasizes the importance of pediatric and medical oncologists being able to identify it in clinic.
Read More
Early Efficacy of BL-B01D1 in a Phase 1 Study Reflects Potential for ADCs in Lung Cancer and Beyond
August 11th 2023Helena A. Yu, MD, discusses the investigation of BL-B01D1 in patients with advanced solid tumors, the potential significance of this research for those with EGFR-mutant and wild-type disease, and the expanding body of evidence supporting continued antibody-drug conjugate development in non–small cell lung cancer.
Read More
SAMETA Trial Evaluates Efficacy of Savolitinib Plus Durvalumab in MET-Driven Papillary RCC
August 10th 2023The safety and efficacy achieved with the combination of savolitinib and durvalumab vs standard-of-care sunitinib or durvalumab monotherapy will be evaluated in patients with MET-driven papillary renal cell carcinoma in the phase 3 SAMETA trial.
Read More
Dana Chase, MD, FACOG, discusses key efficacy, safety, and quality of life data from the RUBY trial supporting the FDA approval of dostarlimab and explains how this approval could help improve the efficacy of current chemotherapy regimens in advanced-stage or recurrent endometrial cancer.
Read More
INDIGO Trial Supports Vorasidenib as Effective Targeted Therapeutic in IDH1/2+ Low-Grade Glioma
August 7th 2023Rimas V. Lukas, MD, reflects on the key points of his presentation delivered at the 2023 Best of ASCO Meeting, which comprised existing unmet needs in low-grade glioma, key efficacy and safety findings from the INDIGO trial, and the viability of vorasidenib-based combination regimens for future investigation.
Read More
BMS-986158–Based Combos May Provide Another Viable Treatment Approach in Myelofibrosis
August 4th 2023Haifa Kathrin Al-Ali, MD, provides background on the phase 1/2 study of BMS-986158, presents initial efficacy and safety data from the study, and discusses her hope that novel combination regimens like these could achieve the challenging goal of disease modification in myelofibrosis in the future.
Read More
Global Consensus-Finding Meeting Aims to Improve the Management of Chondrosarcoma Complications
August 4th 2023R. Lor Randall, MD, FACS, provides details about the 2024 Birmingham Orthopedic Oncology Meeting and its main topic of discussion, explains the rationale for its inception, and emphasizes the importance of this meeting for orthopedic oncologists treating chondrosarcoma.
Read More
Investigation of Ubamatamab With or Without Cemiplimab Continues in Recurrent Ovarian Cancer
August 3rd 2023The preliminary efficacy, safety, and optimal dose of the MUC16xCD3 bispecific antibody ubamatamab alone or in combination with cemiplimab-rwlc continues to be explored in patients with advanced platinum-resistant ovarian cancer in the phase 2 portion of an ongoing, first-in-human, phase 1/2 study.
Read More
Intravenous PRGN-3005 Plus Lymphodepletion Shows Early Promise in Ovarian Cancer
August 2nd 2023Mary “Nora” Disis, MD, expands on key findings from the phase 1/1b study of PRGN-3005, discusses next steps for the trial, and explains how this research aids efforts to effectively utilize CAR T-cell therapy in ovarian cancer and other solid tumors.
Read More
Swetha Kambhampati, MD, explains the need for real-world data on responses to brexu-cel in patients with relapsed/refractory MCL, compares safety and efficacy data from the subgroup analysis with prior results from ZUMA-2, and discusses how these findings support more long-term follow-up in this population.
Read More
ERASur Study Evaluates Total Ablative Therapy Plus Systemic Treatment in mCRC
August 1st 2023The safety and efficacy of adding total ablative therapy of all disease sites to standard systemic treatment is being investigated in patients with limited metastatic colorectal cancer as part of the ongoing phase 3 ERASur study.
Read More
Analysis Helps Distinguish the Molecular Profile of Intraductal Carcinoma of the Prostate
July 31st 2023Benjamin Miron, MD, explains the purpose of studying the molecular profile of intraductal carcinoma of the prostate, expands on the potential prognostic and targetable alterations identified in patients with this histology, and discusses the planned cohort expansion and analysis of RNA signatures in this population.
Read More
Up-front Testing Is Imperative for Treatment Decisions in RET+ NSCLC
July 29th 2023Deborah B. Doroshow, MD, PhD, discusses the efficacy and toxicity profiles of pralsetinib and selpercatinib and how they influence treatment selection for patients with RET fusion–positive non–small cell lung cancer, and provides insight on several areas of ongoing or potential research in lung cancer.
Read More
Tislelizumab Plus Bevacizumab/Chemo Demonstrates Early Efficacy in Cervical Cancer
July 20th 2023The addition of the PD-L1 inhibitor tislelizumab to standard bevacizumab and platinum-doublet chemotherapy in the first-line setting prolonged progression-free survival, produced encouraging responses, and was well tolerated in patients with cervical cancer.
Read More
Frontline SHR-1701 Plus BP102 and Chemo Shows Potent Activity in Cervical Cancer
July 18th 2023The novel bifunctional fusion protein SHR-1701 combined with standard first-line treatment with the bevacizumab biosimilar BP102 and platinum-doublet chemotherapy produced high, durable responses and was deemed tolerable in patients with cervical cancer.
Read More
Key Trials at ASCO 2023 Highlight Role of Perioperative Treatment Approaches in NSCLC
July 13th 2023Jarushka Naidoo, MBBCh, discussed the clinical significance of datasets from several phase 3 trials presented at the 2023 ASCO Annual Meeting, including ADAURA, KEYNOTE-617, CheckMate 816, and CheckMate 9LA trials.
Read More
First-line Enfortumab Vedotin Plus Pembrolizumab Has Durable Activity in Urothelial Carcinoma
July 13th 2023Responses achieved with enfortumab vedotin plus pembrolizumab were found to be rapid and durable in patients with previously untreated locally advanced or metastatic urothelial carcinoma who were cisplatin ineligible.
Read More
Immuno-Oncology Approaches Continue to Advance Across Gynecologic Cancers
July 11th 2023Michael J. Birrer, MD, PhD, highlights the effect of improved molecular characterization in endometrial cancer, the clinical significance of the KEYNOTE-775 trial, and recent changes in the frontline treatment landscape in advanced endometrial cancer.
Read More
Negative Survival Data From CONTACT-03 Call ICI Rechallenge in Advanced RCC Into Question
July 11th 2023Toni K. Choueiri, MD, highlights findings from the CONTACT-03 trial and their clinical significance, as well as the need for continued investigation of PD-1 inhibitor rechallenge despite the negative trial results with cabozantinib and atezolizumab.
Read More
Systemic Therapy Shows Increasing Promise for CNS Metastases in Breast Cancer
July 10th 2023Nancy U. Lin, MD, provides clinical insights on the treatment of patients with breast cancer brain metastases and discusses the advantages and disadvantages of systemic therapy vs radiation therapy for this population.
Read More